Belite Bio reported positive top-line results from the Phase 3 DRAGON trial: tinlarebant reduced the growth rate of retinal lesions in Stargardt disease type 1 by a clinically meaningful margin versus placebo. The trial met its primary efficacy endpoint, positioning tinlarebant as the first potential therapy for STGD1 and advancing Belite toward regulatory submissions. Tinlarebant is an oral small molecule designed to lower retinol-binding protein 4 and thereby reduce retinal toxic byproducts implicated in Stargardt. The company plans to engage regulators on an approval pathway; payors and specialty ophthalmology centers will monitor safety, durability, and real-world adoption metrics. Investors reacted favorably, sending Belite shares higher on the news.